Guardant Health has secured Medicare coverage from Palmetto for its blood test to monitor for disease recurrence in patients with colorectal cancer.
Guardant, a biotechnology company, provides a blood test on Guardant’s Smart Liquid Biopsy platform that uses epigenomic analysis to detect circulating tumor DNA to predict GI cancer recurrence, according to a Jan. 21 news release.
The Guardant Reveal test is now covered by Medicare for use in the CRC surveillance setting after curative intent treatment. Previously, coverage expanded only to testing for CRC in the early post-surgical setting.
Gastroenterologists are facing increasing financial strain as reimbursement rates continue to decline. A study published in The American Journal of…
Law firm Edelson Lechtzin is investigating privacy violations at Gastroenterology Associates of Central Florida, also known as the Center for…
A case in front of the U.S. Supreme Court could limit the U.S. Preventive Services Task Force's role in preventive…